AXIMMUNE

Following completion of preclinical testing, AxImmune intends to file an IND with the FDA. AxImmune anticipates commencing clinical trials in Q4 2019. Plans are underway to conduct clinical trials at multiple sites... AxImmune, Inc. is developing clinical stage immuno-oncology (IO) technology in-licensed from Colorado State University (CSU) and Axon Connected, LLC. Animal studies, including at CSU and respected independent testing labs, indicate that Ax-101 is a potent immuno-modulary agent that works synergistically with immune checkpoint inhibitors (ICI's), such as Keytruda, Yervoy, and Opdivo, improving outcomes and potentially expanding cancers treatable with ICI drugs. Previous Ax-101 single agent human trials show no significant drug related adverse effects and strong anti-tumor activity for patients with functioning immune systems. It is anticipated that co-therapy of Ax-101 and ICI drugs may increase the number of patients who achieve complete recovery and exhibit immunity..

Also known as: AxImmune Inc.

Primary location: Fort Collins United States